GGrantIndex
← Leaderboards

T.-C. Wu

Howard University

$25,440,772
Attributed
$28,640,667
Total exposure
36
Grants
26
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.4M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$81,569,164 · 39

By mechanism

P50$63,475,207 · 20
R01$9,481,955 · 6
P01$3,289,767 · 2
U01$1,394,332 · 1
R21$1,237,398 · 3
P20$1,074,374 · 3

Top collaborators

Most similar at Howard University

Same institution · by research overlap

Others in their field

Top investigators on “Malignant Neoplasm Of Cervix Uteri

Research focus

Malignant Neoplasm Of Cervix UteriProgramsHuman PapillomavirusFundingResearch PersonnelInnovationUniversitiesMalignant NeoplasmsHuman Papillomavirus 16SafetyVaccinationImmune ResponseTranslational ResearchCommunicationAlabamaVaccinesAnticancer ResearchLesionBaseAntigensDna VaccinesTumorCareer DevelopmentImmunology

Grant awards (170)

SPORE in Cervical Cancer$2,261,467
P50 · FY2025 · CA · contact PI
Strategies to Reduce Global Health Disparities in Cervical Cancer$630,506
R01 · FY2025 · CA · contact PI
Therapeutic HPV vaccines (PVX7) for Advanced Cervical Cancer$294,524
P50 · FY2025 · CA · contact PI
Administration/Communication Core$294,503
P50 · FY2025 · CA · contact PI
Developmental Research Program$150,735
P50 · FY2025 · CA · contact PI
Career Enhancement Program$147,520
P50 · FY2025 · CA · contact PI
Howard University Summer Research Education Experience Program in Oral Health$131,800
R25 · FY2025 · DE
SPORE in Cervical Cancer$1,949,494
P50 · FY2024 · CA · contact PI
Administration/Communication Core$268,351
P50 · FY2024 · CA · contact PI
Therapeutic HPV vaccines (PVX7) for Advanced Cervical Cancer$252,436
P50 · FY2024 · CA · contact PI
Howard University Summer Research Education Experience Program in Oral Health$131,800
R25 · FY2024 · DE
Developmental Research Program$114,399
P50 · FY2024 · CA · contact PI
Career Enhancement Program$111,313
P50 · FY2024 · CA · contact PI
SPORE in Cervical Cancer$1,672,035
P50 · FY2023 · CA · contact PI
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy$570,782
R01 · FY2023 · CA · contact PI
A Phase I safety & immunogenicity study of an HPV16-specific therapeutic protein, TA-CIN, administered intratumorally with chemoradiation in patients with cervical cancer stratified by HPV16 infection$297,816
P50 · FY2023 · CA · contact PI
Administrative/Communication Core$165,853
P50 · FY2023 · CA · contact PI
Howard University Summer Research Education Experience Program in Oral Health$133,800
R25 · FY2023 · DE
Development Research Program$129,386
P50 · FY2023 · CA · contact PI
Career Enhancement Program$127,845
P50 · FY2023 · CA · contact PI
SPORE in Cervical Cancer$1,669,823
P50 · FY2022 · CA · contact PI
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy$571,193
R01 · FY2022 · CA · contact PI
A Phase I safety & immunogenicity study of an HPV16-specific therapeutic protein, TA-CIN, administered intratumorally with chemoradiation in patients with cervical cancer stratified by HPV16 infection$362,763
P50 · FY2022 · CA · contact PI
Administrative/Communication Core$200,197
P50 · FY2022 · CA · contact PI
SPORE in Cervical Cancer$199,889
P50 · FY2022 · CA · contact PI
Admin-Core-001$199,889
P50 · FY2022 · CA · contact PI
Development Research Program$159,775
P50 · FY2022 · CA · contact PI
Career Enhancement Program$157,257
P50 · FY2022 · CA · contact PI
SPORE in Cervical Cancer$1,668,414
P50 · FY2021 · CA · contact PI
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy$583,258
R01 · FY2021 · CA · contact PI
Administrative/Communication Core$208,552
P50 · FY2021 · CA · contact PI
Development Research Program$208,551
P50 · FY2021 · CA · contact PI
A Phase I safety & immunogenicity study of an HPV16-specific therapeutic protein, TA-CIN, administered intratumorally with chemoradiation in patients with cervical cancer stratified by HPV16 infection$208,551
P50 · FY2021 · CA · contact PI
Career Enhancement Program$208,551
P50 · FY2021 · CA · contact PI
SPORE in Cervical Cancer$1,704,839
P50 · FY2020 · CA · contact PI
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy$583,657
R01 · FY2020 · CA · contact PI
A Phase I safety & immunogenicity study of an HPV16-specific therapeutic protein, TA-CIN, administered intratumorally with chemoradiation in patients with cervical cancer stratified by HPV16 infection$308,365
P50 · FY2020 · CA · contact PI
Administrative/Communication Core$170,312
P50 · FY2020 · CA · contact PI
Development Research Program$135,650
P50 · FY2020 · CA · contact PI
Career Enhancement Program$133,560
P50 · FY2020 · CA · contact PI
Howard University Summer Research Experience Program in Oral Health Disparity for Underrepresented Racial and Ethnic Students$52,663
R25 · FY2020 · DE
SPORE in Cervical Cancer$1,279,343
P50 · FY2019 · CA · contact PI
Development of Novel Spontaneous HPV Cervicovaginal Carcinoma Models for Cancer Immunotherapy$596,869
R01 · FY2019 · CA · contact PI
A Phase I safety & immunogenicity study of an HPV16-specific therapeutic protein, TA-CIN, administered intratumorally with chemoradiation in patients with cervical cancer stratified by HPV16 infection$227,541
P50 · FY2019 · CA · contact PI
Administrative/Communication Core$121,796
P50 · FY2019 · CA · contact PI
Development Research Program$104,695
P50 · FY2019 · CA · contact PI
Career Enhancement Program$101,796
P50 · FY2019 · CA · contact PI
Howard University Summer Research Experience Program in Oral Health Disparity for Underrepresented Racial and Ethnic Students$52,823
R25 · FY2019 · DE
SPORE in Cervical Cancer$2,251,770
P50 · FY2018 · CA · contact PI
Ovarian cancer gene therapy using HPV pseudovirion$336,150
R01 · FY2018 · CA · contact PI
A Phase I Safety and Immunogenicity Study of a HPV16-Specific Therapeutic Protei$249,080
P50 · FY2018 · CA · contact PI
Administration/Communication$246,497
P50 · FY2018 · CA · contact PI
Developmental Research Program$162,903
P50 · FY2018 · CA · contact PI
Career Development Program$161,579
P50 · FY2018 · CA · contact PI
Howard University Summer Research Experience Program in Oral Health Disparity for Underrepresented Racial and Ethnic Students$52,823
R25 · FY2018 · DE
SPORE in Cervical Cancer$2,300,000
P50 · FY2017 · CA · contact PI
Ovarian cancer gene therapy using HPV pseudovirion$336,150
R01 · FY2017 · CA · contact PI
A Phase I Safety and Immunogenicity Study of a HPV16-Specific Therapeutic Protei$254,559
P50 · FY2017 · CA · contact PI
Administration/Communication$251,905
P50 · FY2017 · CA · contact PI
(2/2) Howard University/Johns Hopkins Partnership in HPV-Related Cancer Research$179,686
P20 · FY2017 · CA · contact PI
Developmental Research Program$166,020
P50 · FY2017 · CA · contact PI
Career Development Program$164,660
P50 · FY2017 · CA · contact PI
Research Pilot Project 1$73,295
P20 · FY2017 · CA · contact PI
Howard University Summer Research Experience Program in Oral Health Disparity for Underrepresented Racial and Ethnic Students$52,823
R25 · FY2017 · DE
SPORE in Cervical Cancer$2,152,942
P50 · FY2016 · CA · contact PI
Ovarian cancer gene therapy using HPV pseudovirion$336,150
R01 · FY2016 · CA · contact PI
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity$303,371
R01 · FY2016 · CA · contact PI
A Phase I Safety and Immunogenicity Study of a HPV16-Specific Therapeutic Protei$238,256
P50 · FY2016 · CA · contact PI
Administration/Communication$235,776
P50 · FY2016 · CA · contact PI
Immune Evasion by Nanog-Mediated Changes to the Tumor Microenvironment.$211,410
R21 · FY2016 · CA · contact PI
(2/2) Howard University/Johns Hopkins Partnership in HPV-Related Cancer Research$184,939
P20 · FY2016 · CA · contact PI
Developmental Research Program$155,475
P50 · FY2016 · CA · contact PI
Career Development Program$154,202
P50 · FY2016 · CA · contact PI
Research Pilot Project 1$74,544
P20 · FY2016 · CA · contact PI
SPORE in Cervical Cancer$2,174,869
P50 · FY2015 · CA · contact PI
Ovarian cancer gene therapy using HPV pseudovirion$336,150
R01 · FY2015 · CA · contact PI
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity$303,371
R01 · FY2015 · CA · contact PI
A Phase I Safety and Immunogenicity Study of a HPV16-Specific Therapeutic Protei$240,679
P50 · FY2015 · CA · contact PI
Administration/Communication$238,172
P50 · FY2015 · CA · contact PI
(2/2) Howard University/Johns Hopkins Partnership in HPV-Related Cancer Research$190,237
P20 · FY2015 · CA · contact PI
Immune Evasion by Nanog-Mediated Changes to the Tumor Microenvironment.$176,175
R21 · FY2015 · CA · contact PI
Upregulation of Nanog as an Innovative Mechanism for Cancer Drug Resistance.$176,175
R21 · FY2015 · CA · contact PI
Developmental Research Program$157,065
P50 · FY2015 · CA · contact PI
Career Development Program$155,781
P50 · FY2015 · CA · contact PI
Research Pilot Project 1$77,793
P20 · FY2015 · CA · contact PI
SPORE in Cervical Cancer$2,162,000
P50 · FY2014 · CA · contact PI
Ovarian cancer gene therapy using HPV pseudovirion$336,150
R01 · FY2014 · CA · contact PI
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity$294,269
R01 · FY2014 · CA · contact PI
A Phase I Safety and Immunogenicity Study of a HPV16-Specific Therapeutic Protei$240,095
P50 · FY2014 · CA · contact PI
Administration/Communication$234,986
P50 · FY2014 · CA · contact PI
Upregulation of Nanog as an Innovative Mechanism for Cancer Drug Resistance.$211,410
R21 · FY2014 · CA · contact PI
Developmental Research Program$158,261
P50 · FY2014 · CA · contact PI
Career Development Program$156,990
P50 · FY2014 · CA · contact PI
(2/2) Howard University/Johns Hopkins Partnership in HPV-Related Cancer Research$146,940
P20 · FY2014 · CA · contact PI
Planning and Priority Setting Phase$146,940
P20 · FY2014 · CA · contact PI
SPORE in Cervical Cancer$2,150,500
P50 · FY2013 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$288,750
P50 · FY2013 · CA
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity$285,169
R01 · FY2013 · CA · contact PI
Administrative Core$262,466
P50 · FY2013 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$193,870
P50 · FY2013 · CA
SPORE in Cervical Cancer$111,720
P50 · FY2013 · CA · contact PI
Career Development Program$93,596
P50 · FY2013 · CA · contact PI
Developmental Research Program$90,831
P50 · FY2013 · CA
SPORE in Cervical Cancer$2,300,000
P50 · FY2012 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$309,265
P50 · FY2012 · CA
Enhancing HPV-16 E6/E7 Specific Antitumor Immunity$303,371
R01 · FY2012 · CA · contact PI
Administrative Core$282,370
P50 · FY2012 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$210,399
P50 · FY2012 · CA
Career Development Program$102,508
P50 · FY2012 · CA · contact PI
Developmental Research Program$99,556
P50 · FY2012 · CA
SPORE in Cervical Cancer$90,231
P50 · FY2012 · CA · contact PI
SPORE in Cervical Cancer$2,185,000
P50 · FY2011 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$305,192
P50 · FY2011 · CA
Administrative Core$280,416
P50 · FY2011 · CA · contact PI
Laser treatment to enhance therapeutic HPV DNA vaccine potency$248,757
R21 · FY2011 · AI · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$208,423
P50 · FY2011 · CA
Career Development Program$103,625
P50 · FY2011 · CA · contact PI
Developmental Research Program$100,715
P50 · FY2011 · CA
SPORE in Cervical Cancer$91,245
P50 · FY2011 · CA · contact PI
SPORE in Cervical Cancer$2,300,000
P50 · FY2010 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$301,914
P50 · FY2010 · CA
Administrative Core$280,712
P50 · FY2010 · CA · contact PI
Laser treatment to enhance therapeutic HPV DNA vaccine potency$213,471
R21 · FY2010 · AI · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$210,262
P50 · FY2010 · CA
Career Development Program$105,593
P50 · FY2010 · CA · contact PI
Developmental Research Program$102,700
P50 · FY2010 · CA
SPORE in Cervical Cancer$2,300,000
P50 · FY2009 · CA · contact PI
Dev. of Optimized/Adjuvanted Smallpox DNA Vaccine (Gene Gun)$528,409
U01 · FY2009 · AI · contact PI
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY$307,116
R01 · FY2009 · CA · contact PI
A phase I trial to assess the safety and immunogenicity of repeated, cluster part$304,161
P50 · FY2009 · CA
Administrative Core$277,611
P50 · FY2009 · CA · contact PI
OVARIAN CANCER MESOTHELIN ANIMAL MODEL/DNA VACCINES$234,577
U19 · FY2009 · CA · contact PI
A phase I trial to assess the immunogenicity, safety, tolerability and efficacy o$212,970
P50 · FY2009 · CA
Career Development Program$108,929
P50 · FY2009 · CA · contact PI
Developmental Research Program$106,022
P50 · FY2009 · CA
SPORE in Cervical Cancer$1,165,045
P50 · FY2008 · CA · contact PI
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY$307,116
R01 · FY2008 · CA · contact PI
Dev. of Optimized/Adjuvanted Smallpox DNA Vaccine (Gene Gun)$283,512
U01 · FY2008 · AI · contact PI
OVARIAN CANCER MESOTHELIN ANIMAL MODEL/DNA VACCINES$234,484
U19 · FY2008 · CA · contact PI
SPORE in Cervical Cancer$2,412,090
P50 · FY2007 · CA · contact PI
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY$306,882
R01 · FY2007 · CA · contact PI
Dev. of Optimized/Adjuvanted Smallpox DNA Vaccine (Gene Gun)$303,292
U01 · FY2007 · AI · contact PI
OVARIAN CANCER MESOTHELIN ANIMAL MODEL/DNA VACCINES$238,914
U19 · FY2007 · CA · contact PI
SPORE in Cervical Cancer$2,585,813
P50 · FY2006 · CA · contact PI
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY$315,083
R01 · FY2006 · CA · contact PI
Dev. of Optimized/Adjuvanted Smallpox DNA Vaccine (Gene Gun)$279,119
U01 · FY2006 · AI · contact PI
OVARIAN CANCER MESOTHELIN ANIMAL MODEL/DNA VACCINES$149,813
U19 · FY2006 · CA · contact PI
SPORE in Cervical Cancer$2,651,995
P50 · FY2005 · CA
ENHANCING HPV-16 E6-SPECIFIC ANTITUMOR IMMUNITY$321,185
R01 · FY2005 · CA
OVARIAN CANCER MESOTHELIN ANIMAL MODEL/DNA VACCINES$149,811
U19 · FY2005 · CA
SPORE in Cervical Cancer$2,450,204
P50 · FY2004 · CA
SPORE in Cervical Cancer$196,200
P50 · FY2004 · CA
SPORE in Cervical Cancer$2,500,000
P50 · FY2003 · CA
HUMAN IMMUNE RESPONSES TO HPV VACCINES$759,441
P01 · FY2003 · AI
PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT$225,712
R01 · FY2003 · CA
IMMUNO- &ANTIANGIOGENESIS THERAPY IN CERVICAL CANCER$0
P50 · FY2003 · CA
HUMAN IMMUNE RESPONSES TO HPV VACCINES$1,125,221
P01 · FY2002 · AI
PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT$219,137
R01 · FY2002 · CA
HER-2/NEU-SPECIFIC PSEUDOVIRION CANCER VACCINES$0
U19 · FY2002 · CA
Characterize E7 specific T cell immune responses for HPV vaccine trials$0
P01 · FY2002 · AI
HUMAN IMMUNE RESPONSES TO HPV VACCINES$715,846
P01 · FY2001 · AI
PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT$213,081
R01 · FY2001 · CA
ENHANCEMENT OF HPV16 E6 &E7-SPECIFIC ANTITUMOR IMMUNITY$179,051
R01 · FY2001 · CA
Characterize E7 specific T cell immune responses for HPV vaccine trials$0
P01 · FY2001 · AI
HER-2/NEU-SPECIFIC PSEUDOVIRION CANCER VACCINES$0
U19 · FY2001 · CA
HUMAN IMMUNE RESPONSES TO HPV VACCINES$689,259
P01 · FY2000 · AI
PREVENTIVE/THERAPEUTIC HPV VACCINE DEVELOPMENT$207,189
R01 · FY2000 · CA
ENHANCEMENT OF HPV16 E6 &E7-SPECIFIC ANTITUMOR IMMUNITY$173,837
R01 · FY2000 · CA
Characterize E7 specific T cell immune responses for HPV vaccine trials$0
P01 · FY2000 · AI
HER-2/NEU-SPECIFIC PSEUDOVIRION CANCER VACCINES$0
U19 · FY2000 · CA